T1	PROC 472 497	Probar la bioequivalencia
T2	PROC 95 134	estudio abierto, cruzado y aleatorizado
#1	AnnotatorNotes T2	C1709323; Open Label Study; Research Activity + C0150097; Cross-Over Studies; Research Activity + C0034656; Randomization; Research Activity
T3	PROC 255 261	tratar
#2	AnnotatorNotes T3	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T4	CHEM 154 191	citrato de fentanilo oral transmucosa
#3	AnnotatorNotes T4	C3853047; Transmucosal Oral Fentanyl Citrate; Organic Chemical
T5	CHEM 193 197	CFOT
#4	AnnotatorNotes T5	C3853047; Transmucosal Oral Fentanyl Citrate; Organic Chemical
T6	CHEM 213 224	medicamento
#5	AnnotatorNotes T6	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T7	CHEM 43 69	fentanilo oral transmucosa
#6	AnnotatorNotes T7	C3853047; Transmucosal Oral Fentanyl Citrate; Organic Chemical
T8	CHEM 507 518	medicamento
#7	AnnotatorNotes T8	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T9	PROC 824 832	instruyó
#8	AnnotatorNotes T9	C0039401; Educational process of instructing; Educational Activity
T10	PROC 579 637	Estudio abierto, cruzado, aleatorizado, de bioequivalencia
T11	CHEM 2209 2213	CFOT
#9	AnnotatorNotes T11	C3853047; Transmucosal Oral Fentanyl Citrate; Organic Chemical
T12	CHEM 786 795	fentanilo
#10	AnnotatorNotes T12	C0015846; Fentanyl; Organic Chemical · Pharmacologic Substance
T13	CHEM 2747 2751	CFOT
#11	AnnotatorNotes T13	C3853047; Transmucosal Oral Fentanyl Citrate; Organic Chemical
T14	ANAT 878 890	mucosa bucal
#12	AnnotatorNotes T14	C0026639; Oral mucous membrane structure; | C1280540; Entire buccal mucosa; Tissue | C1284365; Entire oral mucous membrane; Tissue
T15	PROC 940 951	controlaron
#13	AnnotatorNotes T15	C0030695; Patient Monitoring; Health Care Activity | C0150369; Preventive monitoring; Health Care Activity
T16	PROC 1317 1326	protocolo
#14	AnnotatorNotes T16	C0008971; Clinical Protocols; Therapeutic or Preventive Procedure
T17	CHEM 519 523	CFOT
#15	AnnotatorNotes T17	C3853047; Transmucosal Oral Fentanyl Citrate; Organic Chemical
T18	PROC 957 971	administración
#16	AnnotatorNotes T18	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T19	CHEM 1963 1975	medicamentos
#17	AnnotatorNotes T19	C0013227; Pharmaceutical Preparations; Pharmacologic Substance | C0456386; Medicament; Pharmacologic Substance
T20	DISO 2016 2040	acontecimientos adversos
#18	AnnotatorNotes T20	C0877248; Adverse event; Pathologic Function
T21	CHEM 2092 2096	CFOT
#19	AnnotatorNotes T21	C3853047; Transmucosal Oral Fentanyl Citrate; Organic Chemical
T22	CHEM 2254 2263	fentanilo
#20	AnnotatorNotes T22	C0015846; Fentanyl; Organic Chemical · Pharmacologic Substance
T23	PROC 2401 2413	tratamientos
#21	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	ANAT 2497 2508	plasmáticas
#22	AnnotatorNotes T24	C0032105; Plasma; Body Substance
T25	DISO 265 280	dolor irruptivo
#23	AnnotatorNotes T25	C1135120; Breakthrough Pain; Sign or Symptom
T26	PROC 1761 1788	se probó la bioequivalencia
T27	PROC 2191 2205	administración
#24	AnnotatorNotes T27	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T28	PROC 2340 2354	administración
#25	AnnotatorNotes T28	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T29	DISO 2418 2433	dolor irruptivo
#26	AnnotatorNotes T29	C1135120; Breakthrough Pain; Sign or Symptom
T30	PROC 2654 2668	administración
#27	AnnotatorNotes T30	C1533734; Administration procedure; Therapeutic or Preventive Procedure
T31	DISO 2870 2875	dolor
#28	AnnotatorNotes T31	C0030193; Pain; Sign or Symptom | C0234238; Ache; Sign or Symptom
T32	Route 53 57	oral
#29	AnnotatorNotes T32	C1527415; Oral Route of Drug administration; Functional Concept
T33	Route 175 179	oral
#30	AnnotatorNotes T33	C1527415; Oral Route of Drug administration; Functional Concept
T34	Form 316 332	polvo comprimido
#31	AnnotatorNotes T34	C1337629; COMPRESSED LOZENGE; Biomedical or Dental Material
T35	DEVI 337 346	aplicador
#32	AnnotatorNotes T35	C0336572; Applicator stick; Medical Device
T36	LIVB 374 382	paciente
#33	AnnotatorNotes T36	C0030705; Patients; Patient or Disabled Group
T37	Dose 640 651	dosis única
T39	Duration 738 754	al menos 10 días
T40	LIVB 760 767	sujetos
#34	AnnotatorNotes T40	C0681850; Study Subject; Group
T41	Dose 776 782	400 μg
T42	Frequency 796 804	cada día
T43	Form 857 867	comprimido
#35	AnnotatorNotes T43	C0039225; Tablet Dosage Form; Biomedical or Dental Material
T44	Neg_cue 891 894	sin
T45	PHYS 895 903	chuparlo
#36	AnnotatorNotes T45	C0233927; Sucking; Physiologic Function
T46	Neg_cue 904 906	ni
T47	PHYS 907 917	masticarlo
#37	AnnotatorNotes T47	C0024888; Chewing; Organism Function
T48	LIVB 925 939	investigadores
#38	AnnotatorNotes T48	C0035173; Research Personnel; Professional or Occupational Group
T49	Duration 1005 1015	15 minutos
T50	PHYS 1080 1095	farmacocinética
#39	AnnotatorNotes T50	C0031327; Drug Kinetics; Physiologic Function
T51	LIVB 1268 1275	sujetos
#40	AnnotatorNotes T51	C0681850; Study Subject; Group
T52	Duration 1465 1471	40 min
T53	Duration 1481 1487	50 min
T58	Route 2271 2282	vía enteral
#41	AnnotatorNotes T58	C1522196; Enteral Route of Drug Administration; Functional Concept
T60	Duration 2459 2474	un breve tiempo
T62	LIVB 2712 2721	pacientes
#42	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group
T63	LIVB 2764 2773	pacientes
#43	AnnotatorNotes T63	C0030705; Patients; Patient or Disabled Group
T67	LIVB 73 90	voluntarios sanos
#44	AnnotatorNotes T67	C1708335; Healthy Volunteers; Population Group
T68	LIVB 655 672	voluntarios sanos
#45	AnnotatorNotes T68	C1708335; Healthy Volunteers; Population Group
T69	DEVI 360 366	palito
#46	AnnotatorNotes T69	C0336572; Applicator stick; Medical Device
T38	PHYS 2230 2239	absorción
#47	AnnotatorNotes T38	C0678745; drug absorption; Physiologic Function
T54	PHYS 2296 2305	absorción
#48	AnnotatorNotes T54	C0678745; drug absorption; Physiologic Function
A1	Assertion T45 Negated
A2	Assertion T47 Negated
R1	Negation Arg1:T44 Arg2:T45	
R2	Negation Arg1:T46 Arg2:T47	
T55	Neg_cue 1688 1690	No
T56	Observation 1705 1719	efecto periodo
A3	Assertion T56 Negated
R3	Negation Arg1:T55 Arg2:T56	
T57	Neg_cue 1720 1722	ni
T59	CONC 1723 1732	secuencia
A4	Assertion T59 Negated
R4	Negation Arg1:T57 Arg2:T59	
T61	Quantifier_or_Qualifier 2602 2612	favorecido
A5	Assertion T61 Speculated
T64	Spec_cue 2613 2626	probablemente
T65	Neg_cue 1820 1822	no
T66	CONC 1851 1863	segunda fase
A6	Assertion T66 Negated
R5	Negation Arg1:T65 Arg2:T66	
T70	CONC 1795 1807	primera fase
#49	AnnotatorNotes T66	C0439560; Phase 2; Temporal Concept
#50	AnnotatorNotes T70	C0439559; Phase 1; Temporal Concept
R6	Overlap Arg1:T26 Arg2:T70	
R7	Speculation Arg1:T64 Arg2:T61	
T71	CONC 1 18	Biodisponibilidad
#51	AnnotatorNotes T71	C0005508; Biological Availability; Quantitative Concept
R8	Has_Route_or_Mode Arg1:T7 Arg2:T32	
R9	Experiences Arg1:T67 Arg2:T7	
R10	Has_Route_or_Mode Arg1:T4 Arg2:T33	
R11	Has_Route_or_Mode Arg1:T5 Arg2:T33	
R12	Used_for Arg1:T5 Arg2:T3	
R13	Used_for Arg1:T4 Arg2:T3	
R14	Experiences Arg1:T36 Arg2:T34	
R15	Used_for Arg1:T35 Arg2:T34	
R16	Used_for Arg1:T69 Arg2:T34	
T72	CONC 718 734	tiempo de lavado
#52	AnnotatorNotes T72	C1710661; Washout Period; Temporal Concept
R17	Has_Duration_or_Interval Arg1:T72 Arg2:T39	
R18	Experiences Arg1:T40 Arg2:T12	
R19	Has_Dose_or_Strength Arg1:T12 Arg2:T41	
R20	Has_Frequency Arg1:T12 Arg2:T42	
T73	PHYS 990 1001	se consumía
#53	AnnotatorNotes T73	C1947907; biologic consumption; Physiologic Function (?)
R21	Overlap Arg1:T73 Arg2:T49	
R22	Used_for Arg1:T43 Arg2:T18	
R23	Location_of Arg1:T14 Arg2:T18	
T74	CONC 1123 1138	bioequivalencia
#54	AnnotatorNotes T74	C0039789; Therapeutic Equivalency; Qualitative Concept
T75	CONC 1233 1237	Cmax
#55	AnnotatorNotes T75	C2347813; Cmax; Quantitative Concept
T76	CONC 1243 1249	AUC0-t
R24	Before Arg1:T9 Arg2:T18	
T77	Observation 1276 1298	completaron el estudio
#56	AnnotatorNotes T77	C2732579; Completion of clinical trial; Finding
R26	Experiences Arg1:T51 Arg2:T77	
T78	CONC 1547 1553	AUC0-t
T79	CONC 1680 1686	AUC0-t
T80	CONC 1342 1346	Cmax
#57	AnnotatorNotes T80	C2347813; Cmax; Quantitative Concept
T81	CONC 1673 1677	Cmax
#58	AnnotatorNotes T81	C2347813; Cmax; Quantitative Concept
R27	Overlap Arg1:T80 Arg2:T52	
R28	Overlap Arg1:T80 Arg2:T53	
T82	CONC 1502 1519	biodisponibilidad
#59	AnnotatorNotes T82	C0005508; Biological Availability; Quantitative Concept
T83	CONC 1620 1635	bioequivalencia
#60	AnnotatorNotes T83	C0039789; Therapeutic Equivalency; Qualitative Concept
T84	Observation 1983 1997	bien tolerados
R29	Overlap Arg1:T19 Arg2:T84	
R30	Causes Arg1:T19 Arg2:T20	
T85	Quantifier_or_Qualifier 2044 2059	intensidad leve
#61	AnnotatorNotes T85	C2945599; Mild (qualifier value); Qualitative Concept
R31	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T85	
T86	Quantifier_or_Qualifier 2105 2119	bioequivalente
#62	AnnotatorNotes T86	C0039789; Therapeutic Equivalency; Qualitative Concept
R32	Has_Quantifier_or_Qualifier Arg1:T21 Arg2:T86	
R33	Used_for Arg1:T11 Arg2:T27	
R34	Causes Arg1:T27 Arg2:T38	
R35	Has_Route_or_Mode Arg1:T22 Arg2:T58	
R36	Before Arg1:T28 Arg2:T54	
T87	Quantifier_or_Qualifier 2240 2250	más rápida
R37	Has_Quantifier_or_Qualifier Arg1:T38 Arg2:T87	
R38	Before Arg1:T27 Arg2:T54	
T89	CONC 2518 2522	tmax
#64	AnnotatorNotes T89	C2348796; Tmax; Quantitative Concept
R40	Overlap Arg1:T89 Arg2:T60	
R39	Location_of Arg1:T24 Arg2:T89	
R42	Has_Quantifier_or_Qualifier Arg1:T60 Arg2:T61	
R44	Experiences Arg1:T62 Arg2:T13	
T88	Observation 2859 2875	alivio del dolor
#63	AnnotatorNotes T88	C1998289; Pain relief by medication; Finding
R45	Before Arg1:T31 Arg2:T88	
R46	Experiences Arg1:T63 Arg2:T88	
R47	Experiences Arg1:T63 Arg2:T31	
R48	Experiences Arg1:T62 Arg2:T31	
R49	Experiences Arg1:T62 Arg2:T88	
R51	Before Arg1:T22 Arg2:T54	
#65	AnnotatorNotes T84	C5684674; patient tolerated procedure well; Finding
R52	Experiences Arg1:T36 Arg2:T35	
R53	Experiences Arg1:T36 Arg2:T69	
T90	CONC 482 497	bioequivalencia
#66	AnnotatorNotes T90	C0039789; Therapeutic Equivalency; Qualitative Concept
T91	CONC 622 637	bioequivalencia
#67	AnnotatorNotes T91	C0039789; Therapeutic Equivalency; Qualitative Concept
T92	Quantifier_or_Qualifier 1773 1788	bioequivalencia
#68	AnnotatorNotes T92	C0039789; Therapeutic Equivalency; Qualitative Concept
#69	AnnotatorNotes T56	C4688485; Period Effect; Finding
R25	Used_for Arg1:T22 Arg2:T38	
R50	Used_for Arg1:T11 Arg2:T28	
#70	AnnotatorNotes T1	C3640120; Clinical Bioequivalence or Bioavailability Study; Research Activity
#71	AnnotatorNotes T26	C3640120; Clinical Bioequivalence or Bioavailability Study; Research Activity
A7	Experiencer T67 Patient
A8	Experiencer T36 Patient
A9	Experiencer T68 Patient
A10	Experiencer T40 Patient
A11	Experiencer T48 Other
A12	Experiencer T51 Patient
A13	Experiencer T62 Patient
A14	Experiencer T63 Patient
